Bayer's $7.25 Billion Roundup Deal Wins Final Court Approval After a Decade of Cancer Claims
A Missouri judge has given final approval to Bayer's $7.25 billion settlement of lawsuits claiming its weedkiller Roundup causes cancer, a ruling that could finally close a decade of litigation that has weighed on the German company.
St. Louis Circuit Judge Timothy Boyer ruled on Friday that the nationwide class settlement was fair, reasonable and adequate, calling the total among the largest ever agreed in a mass personal-injury case. The deal covers about 65,000 claims in American state and federal courts from people who say they developed non-Hodgkin lymphoma after using Roundup at home or at work, and it also covers people who are diagnosed in future years.
Under the agreement, Monsanto, the Bayer unit that makes Roundup, will make declining capped annual payments into a fund for up to 21 years, totalling as much as $7.25 billion including money already paid. About $3 billion is due in the first five years. Individual payouts will range from $10,000 to $165,000 depending on how long and how heavily a person was exposed, their age at diagnosis and how severe the illness is. The settlement also sets aside $600 million for lawyers' fees. The approval order can be appealed.
Bayer chief executive Bill Anderson called the ruling a decisive milestone in the company's plan to contain the Roundup litigation. Christopher Seeger, a court-appointed lawyer for the cancer patients, said it delivers guaranteed compensation to victims who have waited more than a decade for justice. The settlement, first announced in February, does not require Bayer to admit liability or wrongdoing, and Bayer continues to say decades of studies show Roundup and its active ingredient glyphosate are safe.
The approval follows a US Supreme Court ruling in June, in a case known as Durnell, in which the court held by 7 votes to 2 that federal pesticide law blocks state lawsuits claiming Bayer failed to warn users about cancer risks. Bayer said the two rulings together reinforce its strategy to contain the litigation. Bayer bought Roundup when it acquired Monsanto in 2018 for $63 billion, and the lawsuits have hung over the company ever since.
Key points
- A Missouri judge gave final approval to Bayer's $7.25 billion settlement of Roundup cancer claims, calling it fair, reasonable and adequate.
- The deal covers about 65,000 current claims and future cases of non-Hodgkin lymphoma, with payouts from $10,000 to $165,000.
- Monsanto will pay into a fund over up to 21 years, with about $3 billion due in the first five years; the approval order can be appealed.
- Bayer admits no liability and says glyphosate is safe; the ruling follows a June Supreme Court decision that weakened failure-to-warn lawsuits.